Workplace violence continues to take a toll on all healthcare settings. Learn more about how nurse leaders play a critical role in advancing safety and implementing technology-driven strategies in today's webinar, Workplace Violence: From Risk to Response (1PM EST). Register Now!
Clinical TopicsWeb Exclusives
first epoetin alfa biosimilar

FDA approves first epoetin alfa biosimilar

Share

On May 15, the U.S. Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.

Read more via FDA.gov.

Poll

Julie NyhusGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • This field is hidden when viewing the form

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts